Genotyping Infarct Patients to Adjust and Normalize Thienopyridine Treatment (GIANT)
Sponsor: Allies in Cardiovascular Trials Initiatives and Organized
Listed as NCT01134380, this observational or N/A phase trial focuses on Acute Coronary Syndrome and Compliance to Thienopyridine Treatment and remains completed. Sponsored by Allies in Cardiovascular Trials Initiatives and Organized, it has been updated 11 times since 2010, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Aug 2017 — Apr 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Aug 2017 [monthly]
Completed PHASE4
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allies in Cardiovascular Trials Initiatives and Organized
- Biotronik France
- European Cardiovascular Research Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Annecy, France , Colmar, France , Corbeil-Essonnes, France , Haguenau, France , Lyon, France , Massy, France , Metz, France , Montpellier, France , Nîmes, France , Paris, France and 2 more locations